2395 Stock Overview
A contract research organization, engages in the transactional research and medipolis businesses in Japan and internationally. More details
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 3/6 |
Past Performance | 1/6 |
Financial Health | 3/6 |
Dividends | 2/6 |
Rewards
Risk Analysis
My Notes
Capture your thoughts, links and company narrative
Shin Nippon Biomedical Laboratories, Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | JP¥1,681.00 |
52 Week High | JP¥1,996.00 |
52 Week Low | JP¥970.00 |
Beta | -0.067 |
1 Month Change | 8.17% |
3 Month Change | 39.27% |
1 Year Change | -2.66% |
3 Year Change | 18.38% |
5 Year Change | 166.40% |
Change since IPO | -23.24% |
Recent News & Updates
Shin Nippon Biomedical Laboratories (TSE:2395) Will Pay A Dividend Of ¥30.00
Dec 19Shin Nippon Biomedical Laboratories (TSE:2395) Is Paying Out A Dividend Of ¥30.00
Dec 02Recent updates
Shin Nippon Biomedical Laboratories (TSE:2395) Will Pay A Dividend Of ¥30.00
Dec 19Shin Nippon Biomedical Laboratories (TSE:2395) Is Paying Out A Dividend Of ¥30.00
Dec 02What Shin Nippon Biomedical Laboratories, Ltd.'s (TSE:2395) 25% Share Price Gain Is Not Telling You
Nov 25Shin Nippon Biomedical Laboratories' (TSE:2395) Dividend Will Be ¥20.00
Sep 19Earnings Miss: Shin Nippon Biomedical Laboratories, Ltd. Missed EPS By 88% And Analysts Are Revising Their Forecasts
Aug 09Little Excitement Around Shin Nippon Biomedical Laboratories, Ltd.'s (TSE:2395) Earnings As Shares Take 28% Pounding
Aug 06Shin Nippon Biomedical Laboratories' (TSE:2395) Dividend Will Be ¥20.00
Jul 26Shin Nippon Biomedical Laboratories' (TSE:2395) Dividend Will Be ¥20.00
Jul 12Shin Nippon Biomedical Laboratories' (TSE:2395) Sluggish Earnings Might Be Just The Beginning Of Its Problems
May 21Shin Nippon Biomedical Laboratories, Ltd. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
May 10Shin Nippon Biomedical Laboratories (TSE:2395) Is Due To Pay A Dividend Of ¥30.00
Mar 12Shin Nippon Biomedical Laboratories (TSE:2395) Has Affirmed Its Dividend Of ¥30.00
Feb 27Shareholder Returns
2395 | JP Life Sciences | JP Market | |
---|---|---|---|
7D | 9.4% | 0.6% | 0.5% |
1Y | -2.7% | -11.1% | 13.6% |
Return vs Industry: 2395 exceeded the JP Life Sciences industry which returned -11.1% over the past year.
Return vs Market: 2395 underperformed the JP Market which returned 13.6% over the past year.
Price Volatility
2395 volatility | |
---|---|
2395 Average Weekly Movement | 5.6% |
Life Sciences Industry Average Movement | 5.6% |
Market Average Movement | 3.6% |
10% most volatile stocks in JP Market | 7.3% |
10% least volatile stocks in JP Market | 1.9% |
Stable Share Price: 2395's share price has been volatile over the past 3 months compared to the JP market.
Volatility Over Time: 2395's weekly volatility (6%) has been stable over the past year, but is still higher than 75% of JP stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1957 | 1,451 | Ryoichi Nagata | www.snbl.co.jp |
Shin Nippon Biomedical Laboratories, Ltd., a contract research organization, engages in the transactional research and medipolis businesses in Japan and internationally. It offers non-clinical studies, including single/repeated dose toxicity studies, antigenicity studies, skin sensitization studies, genotoxicity studies, carcinogenicity studies, local irritation studies, inhalation toxicity studies, TK studies, characteristic studies, stability studies, dependence studies, reproductive and developmental toxicity studies, safety pharmacological studies, and pharmacokinetic studies. The company also engages in the investigator brochure preparation support, clinical trial protocol creation support, clinical trial medical institution, investigational drug allocation, clinical trial request/contract, monitoring, quality management, data management, statistical analysis work, comprehensive report creation support, electronic application support, regulatory affairs consulting, and creating informed consent documents support services.
Shin Nippon Biomedical Laboratories, Ltd. Fundamentals Summary
2395 fundamental statistics | |
---|---|
Market cap | JP¥69.82b |
Earnings (TTM) | JP¥3.90b |
Revenue (TTM) | JP¥27.07b |
18.0x
P/E Ratio2.6x
P/S RatioIs 2395 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
2395 income statement (TTM) | |
---|---|
Revenue | JP¥27.07b |
Cost of Revenue | JP¥12.62b |
Gross Profit | JP¥14.45b |
Other Expenses | JP¥10.56b |
Earnings | JP¥3.90b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 05, 2025
Earnings per share (EPS) | 93.58 |
Gross Margin | 53.38% |
Net Profit Margin | 14.39% |
Debt/Equity Ratio | 95.9% |
How did 2395 perform over the long term?
See historical performance and comparisonDividends
3.0%
Current Dividend Yield53%
Payout RatioDoes 2395 pay a reliable dividends?
See 2395 dividend history and benchmarksShin Nippon Biomedical Laboratories dividend dates | |
---|---|
Ex Dividend Date | Mar 28 2025 |
Dividend Pay Date | Jun 25 2025 |
Days until Ex dividend | 92 days |
Days until Dividend pay date | 181 days |
Does 2395 pay a reliable dividends?
See 2395 dividend history and benchmarksCompany Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/26 07:49 |
End of Day Share Price | 2024/12/26 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Shin Nippon Biomedical Laboratories, Ltd. is covered by 7 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Yuki Tsukamoto | BofA Global Research |
Akitada Iwasa | Daiwa Securities Co. Ltd. |
Masao Yoshida | Ichiyoshi Research Institute Inc. |